Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts

Background The Notch ligand Delta-like 4 (Dll4) is highly expressed in vascular endothelium and has been shown to play a pivotal role in regulating tumor angiogenesis. Blockade of the Dll4-Notch pathway in preclinical cancer models has been associated with non-productive angiogenesis and reduced tumor growth. Given the cross-talk between the vascular endothelial growth factor (VEGF) and Delta-Notch pathways in tumor angiogenesis, we examined the activity of a function-blocking Dll4 antibody, REGN1035, alone and in combination with anti-VEGF therapy in renal cell carcinoma (RCC). Methods and Results Severe combined immunodeficiency (SCID) mice bearing patient-derived clear cell RCC xenografts were treated with REGN1035 and in combination with the multi-targeted tyrosine kinase inhibitor sunitinib or the VEGF blocker ziv-aflibercept. Immunohistochemical and immunofluorescent analyses were carried out, as well as magnetic resonance imaging (MRI) examinations pre and 24 hours and 2 weeks post treatment. Single agent treatment with REGN1035 resulted in significant tumor growth inhibition (36–62%) that was equivalent to or exceeded the single agent anti-tumor activity of the VEGF pathway inhibitors sunitinib (38–54%) and ziv-aflibercept (46%). Importantly, combination treatments with REGN1035 plus VEGF inhibitors resulted in enhanced anti-tumor effects (72–80% growth inhibition), including some tumor regression. Magnetic resonance imaging showed a marked decrease in tumor perfusion in all treatment groups. Interestingly, anti-tumor efficacy of the combination of REGN1035 and ziv-aflibercept was also observed in a sunitinib resistant ccRCC model. Conclusions Overall, these findings demonstrate the potent anti-tumor activity of Dll4 blockade in RCC patient-derived tumors and a combination benefit for the simultaneous targeting of the Dll4 and VEGF signaling pathways, highlighting the therapeutic potential of this treatment modality in RCC.

[1]  Minhong Yan,et al.  Chronic DLL4 blockade induces vascular neoplasms , 2010, Nature.

[2]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[3]  D. Cheresh,et al.  Tumor angiogenesis: molecular pathways and therapeutic targets , 2011, Nature Medicine.

[4]  A. Sood,et al.  Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. , 2011, Cancer research.

[5]  A. Harris,et al.  Vascular Biology , Atherosclerosis and Endothelium Biolog y Expression of Vascular Notch Ligand Delta-Like 4 and Inflammatory Markers in Breast Cancer , 2010 .

[6]  D. Beer,et al.  C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway , 2013, Clinical Cancer Research.

[7]  M. Seshadri,et al.  Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma , 2011, Molecular Cancer Therapeutics.

[8]  A. Harris,et al.  DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. , 2011, Cancer research.

[9]  L. L. Mateos,et al.  Expression of Notch1 to -4 and their ligands in renal cell carcinoma: a tissue microarray study. , 2011, Cancer genomics & proteomics.

[10]  M. Seshadri,et al.  Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. , 2006, Neoplasia.

[11]  Minhong Yan.  Therapeutic promise and challenges of targeting DLL4/NOTCH1 , 2011, Vascular cell.

[12]  Karl J. Dykema,et al.  Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study , 2010, Molecular Cancer Therapeutics.

[13]  D. Qian,et al.  Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model , 2007, Clinical Cancer Research.

[14]  A. Harris,et al.  Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. , 2010, Future oncology.

[15]  Adrian L Harris,et al.  Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. , 2005, Cancer research.

[16]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[17]  A. Gaya,et al.  A preclinical and clinical review of aflibercept for the management of cancer. , 2012, Cancer treatment reviews.

[18]  A. Harris,et al.  Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer , 2011, Clinical Cancer Research.

[19]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[20]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[21]  Gavin Thurston,et al.  Dll4-Notch signaling as a therapeutic target in tumor angiogenesis , 2011, Vascular cell.

[22]  J. Shao,et al.  Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma , 2013, Medical Oncology.

[23]  A. Harris,et al.  Notch regulation of tumor angiogenesis. , 2011, Future oncology.

[24]  A. Gurney,et al.  Anti-DLL4, a cancer therapeutic with multiple mechanisms of action , 2011, Vascular cell.

[25]  Michael F Clarke,et al.  DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. , 2009, Cell stem cell.